
GLP-1 Eye Risk: When Vision Changes Treatment
FDA warnings link GLP-1 drugs such as Ozempic and Wegovy to a possible risk of NAION, a rare condition that can cause sudden vision loss. Dr. Chi-Ming Chow examines how patients and doctors can weigh treatment benefits against this risk, who may need an MMR booster as measles returns, and why routine lipoprotein(a) screening remains debated.
Key Points
- GLP 1 drugs like Ozempic and Wegovy now carry a warning about a rare but serious optic nerve condition, so any vision changes should prompt urgent discussion with both the eye doctor and the prescribing clinician.
- Most adults do not need an MMR booster, but people with uncertain immunity or higher exposure risk such as healthcare workers, travelers, and those in outbreak areas should review their vaccination status.
- Canada is facing rising flu activity and renewed measles control challenges while also gaining a new oral GLP 1 weight loss option, showing how prevention, surveillance, and treatment choices are all evolving at once.
Chapters
| 0:00 | |
| 7:51 | |
| 11:56 | |
| 18:53 |
Transcript
Loading transcript...
- / -

